A detailed history of Barclays PLC transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Barclays PLC holds 8,368 shares of FENC stock, worth $43,513. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,368
Previous 12,876 35.01%
Holding current value
$43,513
Previous $143,000 63.64%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$6.02 - $10.99 $27,138 - $49,542
-4,508 Reduced 35.01%
8,368 $52,000
Q1 2024

May 15, 2024

SELL
$8.82 - $11.12 $107,595 - $135,652
-12,199 Reduced 48.65%
12,876 $143,000
Q4 2023

Feb 15, 2024

BUY
$6.48 - $11.61 $140,065 - $250,950
21,615 Added 624.71%
25,075 $282,000
Q3 2023

Nov 07, 2023

SELL
$7.15 - $8.94 $1,251 - $1,564
-175 Reduced 4.81%
3,460 $26,000
Q2 2023

Aug 03, 2023

SELL
$7.27 - $9.82 $44,070 - $59,528
-6,062 Reduced 62.51%
3,635 $32,000
Q1 2023

May 04, 2023

BUY
$7.38 - $10.35 $3,225 - $4,522
437 Added 4.72%
9,697 $81,000
Q4 2022

Feb 13, 2023

BUY
$7.63 - $10.22 $70,653 - $94,637
9,260 New
9,260 $89,000
Q4 2021

Feb 14, 2022

SELL
$3.89 - $10.01 $10,300 - $26,506
-2,648 Closed
0 $0
Q3 2021

Nov 09, 2021

SELL
$6.51 - $9.62 $2,252 - $3,328
-346 Reduced 11.56%
2,648 $25,000
Q2 2021

Aug 13, 2021

SELL
$5.96 - $7.85 $90,592 - $119,320
-15,200 Reduced 83.54%
2,994 $21,000
Q1 2021

May 13, 2021

BUY
$6.21 - $8.68 $69,365 - $96,955
11,170 Added 159.03%
18,194 $113,000
Q4 2020

Feb 11, 2021

SELL
$5.99 - $8.55 $16,646 - $23,760
-2,779 Reduced 28.35%
7,024 $53,000
Q3 2020

Nov 12, 2020

SELL
$5.19 - $10.17 $11,220 - $21,987
-2,162 Reduced 18.07%
9,803 $60,000
Q2 2020

Aug 12, 2020

BUY
$5.43 - $9.39 $64,969 - $112,351
11,965 New
11,965 $100,000
Q3 2019

Nov 14, 2019

SELL
$3.85 - $4.95 $2,090 - $2,687
-543 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$3.3 - $5.09 $9,480 - $14,623
-2,873 Reduced 84.1%
543 $2,000
Q1 2019

May 15, 2019

BUY
$4.64 - $7.58 $15,850 - $25,893
3,416 New
3,416 $17,000
Q4 2018

Feb 14, 2019

SELL
$5.37 - $8.39 $24,868 - $38,854
-4,631 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$7.84 - $10.83 $29,799 - $41,164
3,801 Added 457.95%
4,631 $38,000
Q2 2018

Aug 14, 2018

BUY
$10.05 - $14.33 $8,341 - $11,893
830 New
830 $8,000

Others Institutions Holding FENC

About FENNEC PHARMACEUTICALS INC.


  • Ticker FENC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,067,300
  • Market Cap $136M
  • Description
  • Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...
More about FENC
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.